(3R,5R,6E,8R,9R,11R,13S,14E,16E,18E,20S,22S,25R,33aS)-Dehexadecahydro Tetradecahydro Sirolimus

Ref. TR-S745120

Informations sur le produit

• Nom: (3R,5R,6E,8R,9R,11R,13S,14E,16E,18E,20S,22S,25R,33aS)-Dehexadecahydro Tetradecahydro Sirolimus
• Synonymes: Sirolimus Impurity C, Rapamycin Impurity C, (3R,5R,6E,8R,9R,11R,13S,14E,16E,18E,20S,22S,25R,33aS)-8,27-dihydroxy-3-((R)-1-((1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl)propan-2-yl)-9,20-dimethoxy-5,7,11,13,19,25-hexamethyl-8,9,12,13,20,21,22,23,24,25,31,32,33,33a-tetradecahydro-22,27-epoxypyrido[2,1-c][1]oxa[4]azacyclotriacontine-1,4,10,26,28(3H,5H,11H,27H,30H)-pentaone
• Marque: TRC
• Description: Applications Rapamycin (R124000) derivative, a triene macrolide antibiotic isolated from Streptomyces hygroscopicus. Name derived from the native word for Easter Island, Rapa’Nui. Used as an immunosuppressant; antirestenotic. Sirolimus (INN/USAN), also known as rapamycin, is an immunosuppressant drug used to prevent rejection in organ transplantation; it is especially useful in kidney transplants.References Martel, P.R., et al.: Can. J. Physiol. Pharmacol., 55, 48 (1977), Carlson, R.P., et al.: J. Pharmacol. Exp. Ther., 266, 1125 (1993), Kahan, B.D., et al.: Lancet, 356, 194 (2000), Holmes, D.R., et al.: Circulation, 109, 634 (2004),

Propriétés chimiques

• Masse moléculaire: 900.145
• Formule: C₅₀H₇₇NO₁₃
• Couleur/Forme: Neat
• InChI: InChI=1S/C50H77NO13/c1-29-16-12-11-13-17-30(2)40(60-8)28-37-21-19-31(3)47(56)50(59,64-37)49(58)51-23-15-14-18-38(51)48(57)63-45(35(7)26-36-20-22-39(52)41(27-36)61-9)42(53)33(5)25-34(6)44(55)46(62-10)43(54)32(4)24-29/h11-13,16-17,25,29,31-33,35-41,44-46,52,55,59H,14-15,18-24,26-28H2,1-10H3/b13-11+,16-12+,30-17+,34-25+/t29-,31-,32-,33?,35-,36+,37+,38+,39-,40+,41-,44-,45-,46+,50?/m1/s1
• Code InChI: InChIKey=WSRYOFHFIGSVMV-PVTVUKMRSA-N
• SMILES: CO[C@H]1C[C@@H]2CC[C@@H](C)C(=O)C(O)(O2)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)C(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C